ImpediMed Limited

ASX:IPD Stock Report

Market Cap: AU$101.8m

ImpediMed Valuation

Is IPD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IPD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IPD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IPD's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IPD?

Key metric: As IPD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IPD. This is calculated by dividing IPD's market cap by their current revenue.
What is IPD's PS Ratio?
PS Ratio8x
SalesAU$12.72m
Market CapAU$101.81m

Price to Sales Ratio vs Peers

How does IPD's PS Ratio compare to its peers?

The above table shows the PS ratio for IPD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10.8x
CYC Cyclopharm
3.1x36.66%AU$96.7m
MX1 Micro-X
5.4x38.43%AU$70.1m
CMP Compumedics
1.1x18.67%AU$57.7m
EMV EMVision Medical Devices
33.6x16.38%AU$169.6m
IPD ImpediMed
8x47.89%AU$101.8m

Price-To-Sales vs Peers: IPD is good value based on its Price-To-Sales Ratio (8x) compared to the peer average (10.8x).

Price to Sales Ratio vs Industry

How does IPD's PS Ratio compare vs other companies in the AU Medical Equipment Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
SDI SDI
1x6.19%US$70.57m
CMP Compumedics
1.1x18.67%US$38.04m
NXS Next Science
1.3xn/aUS$28.95m
UBI Universal Biosensors
0.7xn/aUS$2.76m
IPD 8.0xIndustry Avg. 6.5xNo. of Companies9PS0612182430+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: IPD is expensive based on its Price-To-Sales Ratio (8x) compared to the Australian Medical Equipment industry average (6.6x).

Price to Sales Ratio vs Fair Ratio

What is IPD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IPD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8x
Fair PS Ratio22.8x

Price-To-Sales vs Fair Ratio: IPD is good value based on its Price-To-Sales Ratio (8x) compared to the estimated Fair Price-To-Sales Ratio (22.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IPD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.05
AU$0.11
+120.28%
26.86%AU$0.14AU$0.07n/a3
Sep ’26AU$0.039
AU$0.11
+182.41%
26.86%AU$0.14AU$0.07n/a3
Aug ’26AU$0.047
AU$0.15
+211.02%
13.72%AU$0.17AU$0.12n/a3
Jul ’26AU$0.039
AU$0.15
+274.95%
13.72%AU$0.17AU$0.12n/a3
Jun ’26AU$0.03
AU$0.15
+391.37%
13.80%AU$0.17AU$0.12n/a3
May ’26AU$0.036
AU$0.15
+315.44%
14.17%AU$0.17AU$0.12n/a3
Apr ’26AU$0.042
AU$0.15
+260.39%
14.17%AU$0.17AU$0.12n/a3
Mar ’26AU$0.043
AU$0.13
+213.19%
23.51%AU$0.17AU$0.09n/a4
Feb ’26AU$0.055
AU$0.14
+153.95%
23.53%AU$0.17AU$0.09n/a4
Jan ’26AU$0.052
AU$0.15
+180.13%
27.05%AU$0.19AU$0.09n/a4
Dec ’25AU$0.051
AU$0.15
+185.63%
27.05%AU$0.19AU$0.09n/a4
Nov ’25AU$0.055
AU$0.15
+164.85%
27.05%AU$0.19AU$0.09n/a4
Oct ’25AU$0.059
AU$0.15
+157.97%
26.37%AU$0.20AU$0.09AU$0.0374
Sep ’25AU$0.048
AU$0.16
+243.13%
13.90%AU$0.20AU$0.14AU$0.0394
Aug ’25AU$0.06
AU$0.17
+178.07%
14.24%AU$0.20AU$0.14AU$0.0474
Jul ’25AU$0.071
AU$0.18
+146.93%
15.00%AU$0.20AU$0.14AU$0.0394
Jun ’25AU$0.076
AU$0.18
+130.68%
15.00%AU$0.20AU$0.14AU$0.034
May ’25AU$0.08
AU$0.18
+119.15%
15.00%AU$0.20AU$0.14AU$0.0364
Apr ’25AU$0.092
AU$0.18
+97.14%
16.15%AU$0.20AU$0.14AU$0.0423
Mar ’25AU$0.093
AU$0.18
+95.02%
16.15%AU$0.20AU$0.14AU$0.0433
Feb ’25AU$0.10
AU$0.22
+105.54%
16.19%AU$0.26AU$0.18AU$0.0553
Jan ’25AU$0.14
AU$0.22
+51.67%
15.48%AU$0.26AU$0.18AU$0.0523
Dec ’24AU$0.14
AU$0.22
+57.09%
15.48%AU$0.26AU$0.18AU$0.0513
Nov ’24AU$0.10
AU$0.27
+159.22%
30.62%AU$0.39AU$0.21AU$0.0553
Oct ’24AU$0.17
AU$0.23
+29.07%
52.42%AU$0.39AU$0.06AU$0.0594
AU$0.11
Fair Value
54.6% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/06 02:16
End of Day Share Price 2025/10/06 00:00
Earnings2025/06/30
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ImpediMed Limited is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dennis HulmeAPP Securities Pty Ltd.
Matthijs SmithCanaccord Genuity
Elyse ShapiroCanaccord Genuity